<DOC>
	<DOCNO>NCT00005792</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity potential efficacy intensive high dose chemotherapy consist melphalan , topotecan , etoposide phosphate follow autologous stem cell transplantation patient stage II III multiple myeloma stage I evidence progressive disease . II . Determine maximum tolerate dose topotecan combination melphalan etoposide phosphate patient population . III . Determine response rate time treatment failure patient treat regimen . IV . Determine pharmacokinetic profile drug investigate pharmacodynamic relationship respect efficacy toxicity regimen patient . V. Determine whether sequence chemotherapy regimen appropriate optimal patient . OUTLINE : This dose escalation study topotecan . Patients prim cyclophosphamide IV 2 hour 2 day . Peripheral blood stem cell ( PBSC ) collect . Approximately 4 week PBSC collection , patient receive melphalan IV 30 minute topotecan IV 30 minute day -7 -5 . Etoposide phosphate IV administer 4 hour day -4 -3 . PBSC reinfused day 0 . Cohorts 4-12 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 6 12 patient experience dose limit toxicity . Patients follow 2-3 time week approximately 1 month , 3 , 6 , 12 month . PROJECTED ACCRUAL : A total 34-60 patient accrue study within 24-36 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma Newly diagnose , drug sensitive ( i.e. , great 50 % response standard chemotherapy ) , poor prognostic indicator ( e.g. , SalmonDurie stage III , serum beta2microglobulin great 3.0 ug/L , high proliferative fraction , hypodiploidy ) OR Relapsed response standard chemotherapy OR Primary refractory disease No active leptomeningeal involvement History prior CSF tumor involvement without symptom sign allow provide CSF free disease lumbar puncture MRI brain show tumor involvement No severe symptomatic CNS disease etiology PATIENT CHARACTERISTICS : Age : 15 69 Performance status : ECOG 01 ECOG 34 secondary bone pain potentially reversible disease relate problem eligible investigator 's discretion Life expectancy : At least 12 week Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 2.5 time upper limit normal No history severe hepatic dysfunction Renal : Creatinine great 2.0 mg/dL OR Creatinine least 40 mL/min No hemodialysis peritoneal dialysis Cardiovascular : No evidence severe cardiac dysfunction Ejection fraction least 50 % MUGA scan No major heart disease Essential hypertension control medication allow Pulmonary : DLCO least 50 % normal No symptomatic obstructive restrictive pulmonary disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychosocial disorder would preclude study compliance No active infection No uncontrolled insulin dependent diabetes mellitus No uncompensated major thyroid adrenal dysfunction No prior malignancy except nonmelanoma skin cancer HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior total dose doxorubicin daunorubicin great 450 mg/m2 No prior topotecan topoisomerase I inhibitor , etoposide , etoposide phosphate , teniposide Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent nitroglycerin preparation angina pectoris No concurrent antiarrhythmic drug major ventricular dysrhythmias</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>